Currently, about half of the U.S. COVID-19 vaccine stock is supplied by Moderna. Allowing the drugmaker to fit 14 doses into its vials could increase the country’s vaccine supply by as much as 20 percent.
The agency gave Moderna approval to make the switch so that the national COVID-19 vaccine supply can increase at a faster rate, but it asked the drugmaker to produce more data showing that storing 14 doses in each vial will not compromise the vaccine’s efficacy, according to the Times.
Reworking Moderna’s manufacturing operations to accommodate the switch could be done before the end of April, two anonymous sources familiar with the drugmaker’s production told the Times.
More articles on pharmacy:
Pharmacy chains on hiring sprees to support COVID-19 vaccination campaign
FDA authorizes new COVID-19 antibody cocktail from Eli Lilly
How retail pharmacies plan to handle leftover COVID-19 vaccine doses
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.